Solvias Company Market Research Report
Company Overview
Name
Solvias
Mission
Partnering with life science innovators to achieve commercialization goals.
Founded
- Year: 1999
- By Whom: Founded after being part of Novartis.
Key People
- Archie Cullen: Chief Executive Officer
- Marcel Werder: Vice President, Head of Finance, Solvias Group
- Ilya Koltover, PhD: Chief Commercial Officer
- Alexandra Schneider, PharmD: Chief Quality Officer
- Daniel Galbraith, PhD: Chief Scientific Officer
- José Videira, MBA: Chief Information Officer
- Amale von Planta: Chief Strategy and M&A Officer
- Steve Smith, MBA: General Manager, United States
- David McClelland: Vice President of Operational Transformation
Headquarters
- Location: Kaiseraugst, Switzerland
Number of Employees
- Total: 800+ team members in Europe & U.S.
Revenue
No information is available.
Known For
Solvias is known for its expertise in chemistry, manufacturing, and control (CMC) analytics to the pharmaceutical, biotech, material science, and cosmetic industries.
Products
Ligands & Catalysts
- Description: Solvias offers a library of over 700 high-quality ligands and catalysts for chemical synthesis. They support a wide range of catalytic transformations.
- Key Features:
- Reliable supply.
- In-house use test before committing to purchase.
- Consistent quality from milligram to bulk quantities.
- Access to Solvias expertise from lead finding to implementation.
Process Analytical Technology (PAT)
- Description: Offers fiber optic probes and flow cells for real-time, online, and inline analysis tailored for complex conditions.
- Key Features:
- Real-time analysis using fiber optic probes.
- Robust sapphire optics.
- Support for regulatory acceptance and compliance.
- Customized solutions tailored to specific requirements.
- Increased process and product safety.
Recent Developments
New Partnerships and Collaborations
- Cergentis Acquisition: Solvias acquired Cergentis in July 2022 to bolster biologics and cell & gene therapy capabilities.
- Vertex Pharmaceuticals: Long-term agreement with Vertex Pharmaceuticals for CRISPR-based gene-editing therapy, CASGEVY™.
New Products Launched
No information is available.
New Features Added to Existing Products
No information is available.
Recent News
- July 3, 2024: Cergentis is now operating as Solvias NL.
- June 4, 2024: Elemental Analysis Lab receives “Green” certification from My Green Lab.
- May 6, 2024: Solvias is building a Biologics and Cell & Gene Therapy Testing Center in Research Triangle Park.
- January 23, 2024: Solvias to perform release testing on the world’s first CRISPR-based gene-editing therapy.
Contact Information
- Email: info@solvias.com
- Website: [Solvias](https://www.solvias.com)
© 2024 Solvias. All rights reserved.
